2013


To access this material please log in or register

Register Authorize
2013/№3

Dabigatran for atrial fibrillation: from RE-LY to real life practice

Kastanayan A. A., Arutyunov G. P.

Keywords: anticoagulants, stroke, therapy, atrial fibrillation

DOI: 10.18087/rhj.2013.3.1762

Three million earth dwellers yearly suffer stroke induced by atrial fibrillation (AF). AF not only 5 times increases the risk of stroke but also aggravates the stroke outcome; stroke associated with AF more often results in death and disability than stroke without AF. Prevention of stroke and thromboembolism is a priority therapeutic goal of AF treatment and antithrombotic therapy is a well-accepted method of primary and secondary prevention. Despite obvious clinical benefits in reducing the risk of stroke and thromboembolism, administration of vitamin K antagonists is complicated in some cases with severe hemorrhage, especially intracranial hemorrhage, which may lead to destructive sequences. Due to the concerns about fatal hemorrhage and difficulties in managing patients, the frequency of prescribing vitamin K antagonists remains low and does not correspond to the estimated risk of stroke. Novel oral anticoagulants (NOAC), dabigatran, rivaroxaban and apixaban, as distinct from varfarin, do not require INR monitoring and they have demonstrated a capability for reducing the incidence of intracranial hemorrhage. The direct thrombin inhibitor dabigatran more effectively than varfarin reduces the risk of both ischemic and hemorrhagic stroke with a similar risk of hemorrhage. Although data of clinical studies have convincingly supported the NOAC efficacy and good safety profile, it should be always kept in mind that the clinical experience of using these drugs is still limited and their administration requires continuous monitoring, alertness and regular reviewing the information on results of their use in clinical practice.
  1. World Heart Federation Report 2011, WHO. Available at: http://www.world-heart-federation.org / about-us / annual-reports / 
  2. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: The Framingham study. Stroke. 1996;27 (10):1760–1764.
  3. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27 (8):949–953.
  4. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004;110 (9):1042–1046.
  5. Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J. 2004;25 (19):1734–1740.
  6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146 (12):857–867.
  7. Sherman DG, Kim SG, Boop BS et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165 (10):1185–1191.
  8. Lip GY, Andreotti F, Fauchier L et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106 (6):997–1011.
  9. Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151 (5):297–305.
  10. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154 (13):1449–1457.
  11. SPAF Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343 (8899):687–691.
  12. DiMarco JP, Flaker G, Waldo AL et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the AFFIRM Study. Am Heart J. 2005;149 (4):650–656.
  13. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362 (9397):1691–1698.
  14. Albers GW, Diener HC, Frison L et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293 (6):690–698.
  15. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367 (9526):1903–1912.
  16. Connolly SJ, Ezekowitz MD, Yusuf S et al, for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361 (12):1139–1151.
  17. Flaherty ML, Kissela B, Woo D et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68 (2):116–121.
  18. van Walraven C, Hart RG, Connolly S et al., Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators. Stroke. 2009;40 (4):1410–1416.
  19. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121 (13):1523–1532.
  20. Fang MC, Go AS, Chang Y et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3 (6):624–631.
  21. Granger CB, Alexander JH, McMurray JJ et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365 (11):981–992.
  22. Nieuwlaat R, Capucci A, Lip GY et al. Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27 (24):3018–3026.
  23. Mazzaglia G, Filippi A, Alacqua M et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost. 2010;103 (5):968–975.
  24. Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163 (1):13–19.e1
  25. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–1434.
  26. Kearon C, Ginsberg JS, Kovacs M, et al. Low-intensity (INR 1.5–1.9) versus conventional-intensity (INR 2.0–3.0) anticoagulation for extended treatment of unprovoked VTE: a randomized double blind trial. Blood 2002;100:150a. abstract.
  27. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011. Доступно на: http://cardiocity.ru / natsionalnye-rekomendatsii-po-diagnostike-i-lecheniyu-fibrillyatsii-predserdij-2011
  28. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287 (13):1690–1698.
  29. Reitsma PH, van der Heijden JF, Groot AP et al. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005;2 (10):e312.
  30. Namazi S, Azarpira N, Hendijani F et al. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther. 2010;32 (6):1050–1060.
  31. Stroke Prevention in Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation Study, Final Results. Circulation. 1991;84 (2):527–539.
  32. Connolly SJ, Eikelboom J, Joyner C et al, for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364 (9):806–817.
  33. Olesen JB, Lip GY, Lindhardsen J et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106 (4):739–749.
  34. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33 (21):2719–2747.
  35. Patel MR, Mahaffey KW, Garg J et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365 (10):883–891.
  36. Wann LS, Curtis AB, January CT et al. 2011 ACCF / AHA / HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123 (1):104–123.
  37. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Guidelines for the management of atrial fibrillation European Heart Journal doi:10.1093 / eurheartj / ehq278Camm AJ, Lip GYH, Schotten U et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (developed with the special contribution of the European Heart Rhythm Association, endorsed by the European Association for Cardio-Thoracic Surgery). Eur Heart J. 2010;31 (19):2369–2429.
  38. Skanes AC, Healey JS, Cairns JA et al, and the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate / Rhythm Control. Can J Cardiol. 2012;28 (2):125–136.
  39. Pengo V, Crippa L, Falanga A et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106 (5):868–876.
  40. Testa L, Agnifili M, Latini RA et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM. 2012;105 (10):949–957.
  41. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012;60 (8):738–746.
  42. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical bene­fit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107 (3):584–589.
  43. Furie KL, Goldstein LB, Albers GW et al. American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association / American Stroke Association. Stroke. 2012;43 (12):3442–3453.
  44. European Medicines Agency. European Medicines Agency updates patient and prescriber information for Pradaxa [press release]. May 25, 2012. Available at: http://www.ema.europa.eu / ema / index.jsp?curl=pages / news_and_events / news / 2012 / 05 / news_detail_001518.jsp&mid=WC0b01ac058004d5c1
  45. European Medicines Agency. European Medicines Agency updates on safety of Pradaxa [press release]. November 18, 2011. Available at: http://www.ema.europa.eu / docs / en_GB / document_library / Press_release / 2011 / 11 / WC500117818.pdf
  46. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366 (9):864–866.
  47. Parikh V, Chainani V, Howard M et al. Is dabigatrane safe in real life? J Am Coll Cardiol 2012;59 (13s1):E 602‑E602.
  48. Rajdev A, Bradley J, Petrini J et al. A community experience of the novel anticoagulant pradaxa. J Am Coll Cardiol 2012; 59 (13s1):E 601‑E601.
  49. Wurster MW, Howard M, Price C et al. Dabigatran use in the real world: Preliminary results of a prospective trial comparing outcomes with dabigatran and warfarin therapy. Am J Hematol 2012; 87: S146‑S200.
  50. Apostolakis S, Lane DA, Guo Y et al. Performance of the HEMORR (2) HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60 (9):861–867.
  51. Poli D, Antonucci E, Testa S et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124 (7):824–829.
  52. Legrand M, Mateo J, Aribaud A et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171 (14):1285–1286.
  53. Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients is caution necessary?: Comment on «The use of dabigatran in elderly patients». Arch Intern Med. 2011;171 (14):1287–1288.
  54. Oldgren J, Alings M, Darius H et al. RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155 (10):660–667.
  55. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103 (6):1116–1127.
  56. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124 (14):1573–1579.
  57. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108 (2):217–224.
  58. van Ryn J, Litzenburger T, Waterman A et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol. 2011;57 (14s1):E1130‑E1130.
  59. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154 (1):1–11.
  60. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123 (22):2562–2570.
  61. Deitelzweig S, Amin A, Jing Y, et al. Comparison of total medical cost avoidance with the usage of new oral anticoagulants instead of warfarin among atrial fibrillation patients, based on the ARISTOTLE, RE-LY and ROCKET-AF trials. J Am Coll Cardiol. 2012;59 (13s1):E599‑E599.
  62. Sié P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011;104 (12):669–676
  63. Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23 (3):264–268.
  64. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59 (13):1168–1174.
  65. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123 (2):131–136.
  66. Gage BF. Can we rely on RE-LY? N Engl J Med. 2009;361 (12):1200–1202.
  67. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363 (19):1875–1876.
  68. Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125 (5):669–676.
  69. European Medicines Agency. EMA / 556143 / 2012. Committee for Medicinal Products for Human Use (CHMP) Assessment report. Pradaxa. Procedure No.: EMEA / H / C / 000829 / II / 0031. 23 August 2012.
  70. PL Detail-Document, Dabigatran and Risk of Myocardial Infarction. Pharmacist’s Letter / Prescriber’s Letter. March 2012. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: metaanalysis of noninferiority randomized controlled trials. Available at: http://prescribersletter.therapeuticresearch.com / pl / DD_pu.aspx?­cs=­&s=­PRL&pt=3&fpt=31&dd=280321&pb=PRL&segment=
  71. Lee IO, Kratz MT, Schirmer SH et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2012;343 (2):253–257.
  72. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366 (1):9–19.
  73. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123 (21):2363–2372.
  74. Ruiz-Nodar JM, Marín F, Roldán V et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv. 2012 Aug 1;5 (4):459–466.
  75. Lip GY, Huber K, Andreotti F et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and / or undergoing coronary stenting: executive summary – a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31 (11):1311–1318.
  76. Alexander JH, Lopes RD, James S et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365 (8):699–708.
  77. Matute MC, Masjuan J, Egido JA et al. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis. 2012;33 (3):231–239.
Kastanayan A. A., Arutyunov G. P. Dabigatran for atrial fibrillation: from RE-LY to real life practice. Russian Heart Journal. 2013;12(3):172-185

To access this material please log in or register

Register Authorize
Ru En